Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside

Bibliography

• Christoffersen T, Guren TK, Dahl O, Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results and unresolved issues. Eur J Pharmacol 2009;625:6-22
   PubMed Web of Science ®Google Scholar
• Went P, Vasei M, Bubendorf L, Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006;94:128-35
   PubMed Web of Science ®Google Scholar
• Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer 2004;40:1292-301
   PubMed Web of Science ®Google Scholar
• Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 1979;76:1438-42
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Victor-Kobrin C, Timblin CR, A murine cDNA encodes a pan-epithelial glycoprotein that is also expressed on plasma cells. J Immunol 1992;148:590-6
   PubMed Web of Science ®Google Scholar
• Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699-712
   PubMed Web of Science ®Google Scholar
• Linnenbach AJ, Seng BA, Wu S, Retropositon in a family of carcinoma-associated antigens genes. Mol Cell Biol 1993;13:1507-15
   PubMed Web of Science ®Google Scholar
• Chong JM, Speicher DW. Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM). J Biol Chem 2001;276:5804-13
   PubMed Web of Science ®Google Scholar
• Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003;2:320-26
   PubMed Web of Science ®Google Scholar
• Litvinov SV, Velders MP, Bakker HA, Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 1994;125:437-46
   PubMed Web of Science ®Google Scholar
• Münz M, Kieu C, Mack B, The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58
   PubMed Web of Science ®Google Scholar
• Maetzel D, Denzel S, Mack B, Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-71
   PubMed Web of Science ®Google Scholar
• Osta WA, Chen Y, Mikhitarian K, EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24
   PubMed Web of Science ®Google Scholar
• Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69:5627-29
   PubMed Web of Science ®Google Scholar
• Gastl G, Spizzo G, Obrist P, G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-82
   PubMed Web of Science ®Google Scholar
• Spizzo G, Went P, Dirnhofer S, Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-8
   PubMed Web of Science ®Google Scholar
• Yanamoto S, Kawasaki G, Yoshitomi I, Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007;43:869-77
   PubMed Web of Science ®Google Scholar
• Fong D, Steurer M, Obrist P, Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol 2008;61:31-5
   PubMed Web of Science ®Google Scholar
• Carpenter G, Red Brewer M. EpCAM: another surface-to-nucleus missile. Cancer Cell 2009;15:165-6
   PubMed Web of Science ®Google Scholar
• Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med 2000;124(6):921-3
   PubMed Web of Science ®Google Scholar
• Presta LG. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 2006;58:640-56
   PubMed Web of Science ®Google Scholar
• Saif MW, Syrigos KI, Hotchkiss S, Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2009;65:107-12
   PubMed Web of Science ®Google Scholar
• Riethmüller G, Schneider-Gädicke E, Schlimok G, Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 1994;343:1177-83
   PubMed Web of Science ®Google Scholar
• Fields AL, Keller A, Schwartzberg L, Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. J Clin Oncol 2009;27:1941-47
   PubMed Web of Science ®Google Scholar
• Punt CJ, Nagy A, Douillard JY, Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002;360:671-77
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6(4):443-6
   PubMed Web of Science ®Google Scholar
• Raum T, Gruber R, Riethmüller G, Kufer P. Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens. Cancer Immunol Immunother 2001;50:141-45
   PubMed Web of Science ®Google Scholar
• Naundorf S, Preithner S, Mayer P, In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002;100:101-10
   PubMed Web of Science ®Google Scholar
• Xiang W, Wimberger P, Dreier T, Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol 2003;129:341-8
   PubMed Web of Science ®Google Scholar
• Prang N, Preithner S, Brischwein K, Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005;92:342-49
   PubMed Web of Science ®Google Scholar
• Velders MP, van Rhijn CM, Briaire IH, Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 1995;55:4398-403
   PubMed Web of Science ®Google Scholar
• Lutterbuese P, Brischwein K, Hofmeister R, Exchanging human Fcgamma1 with murine Fcgamma2 highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother 2007;56:459-68
   PubMed Web of Science ®Google Scholar
• Rüttinger D, Brand C, Simmich C, ADCC-mediated lysis of KRAS-mutated colon cancer cells by anti-EpCAM antibody adecatumumab [abstract]. J Immunother 2008;31:971
   Web of Science ®Google Scholar
• Oberneder R, Weckermann D, Ebner B, A Phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer 2006;42:2530-38
   PubMed Web of Science ®Google Scholar
• Sebastian M, Hanusch C, Schmidt M, Safety and antitumor activity of 3 weekly anti-EpCAM antibody adecatumumab in combination with docetaxel for patients with metastatic breast cancer: results of a multicenter Phase Ib trial [abstract]. J Clin Oncol 2009;27(15s):1009
   Google Scholar
• Schmidt M, Scheulen ME, Dittrich C, An open-label, randomized Phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010;21(2):275-82
   PubMed Web of Science ®Google Scholar
• Marschner N, Rüttinger D, Zugmaier G, Phase II study of the human anti-EpCAM antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate specific antigen after radical prostatectomy. Br J Urol Int (In press)
   Google Scholar
• Allegra CJ, Jessup JM, Somerfield MR, American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27(12):2091-6
   PubMed Web of Science ®Google Scholar
• de Bono JS, Tolcher AW, Forero A, ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004;10(22):7555-65
   PubMed Web of Science ®Google Scholar